SAN JOSE, Calif., Sept. 23, 2024 /PRNewswire/ — AHEAD Medicine Corporation, a pioneering AI HealthTech company, is excited to announce a significant advancement in its flagship product, Cyto-Copilot. The new analysis module now supports AML versus non-neoplastic diagnostic classification across five different flow cytometry test panels and instrument models. This groundbreaking development will be presented at the upcoming European Society of Clinical Cytometry Analysis (ESCCA) 2024 and International Clinical Cytometry Society (ICCS) 2024 conferences under the title “Enhancing Accessibility and Reproducibility of Flow Cytometry Data Analysis with Panel-Agnostic Machine Learning-Based Automated Cross-Panel Classification for Acute Leukemia.”
Cyto-copilot is an advanced artificial intelligence (AI)-driven platform engineered to transform the analysis of complex clinical flow cytometry data. The platform integrates a suite of machine learning models and visualization tools to …